KPV
KPV
Also known as: KPV Tripeptide, Alpha-MSH Fragment 11-13
Overview
Key Facts
Primary Goal: A tripeptide fragment from the C-terminus of alpha-melanocyte stimulating hormone (alpha-MSH)
A tripeptide fragment from the C-terminus of alpha-melanocyte stimulating hormone (alpha-MSH). Possesses potent anti-inflammatory and antimicrobial properties without melanogenic effects. Particularly relevant for immune regulation in gut and mucosal tissues. Half-Life ~30 minutes Typical Dose 200–500 mcg Frequency 1-2x daily Cycle Length 4-12 weeks
Dosing Information
Half-Life
~30 minutes
Typical Dose
200–500 mcg
Frequency
1-2x daily
Cycle Length
4-12 weeks
Administration Routes:
Storage & Reconstitution
Unreconstituted (Powder)
Reconstituted (Mixed)
Research Summary
Studied in preclinical models of inflammatory bowel disease, colitis, and skin inflammation. Demonstrated efficacy comparable to standard anti-inflammatory treatments in murine IBD models. Strong in vitro evidence for NF-kB inhibition. Cross-reference: see kpv in healing-recovery for tissue repair context.
Frequently Asked Questions
Common questions about KPV
UK-Specific Information
Exclusive data points and guidance for UK residents using KPV
UK Lab Testing
US Lab Testing
Recommended labs: Quest Diagnostics, LabCorp ($120-$200 for peptide safety panel)
Why this matters: UK-specific lab testing guidance not available on US competitor sites
Commonly Stacked With
5-Amino-1MQ
Research and therapeutic applications of 5-Amino-1MQ
Ac-SDKP
Research and therapeutic applications of Ac-SDKP
ACE-031
Research and therapeutic applications of ACE-031
Acetyl Hexapeptide-3
Research and therapeutic applications of Acetyl Hexapeptide-3
AHK-Cu
Research and therapeutic applications of AHK-Cu
Alcohol Prep Pads
Research and therapeutic applications of Alcohol Prep Pads
Note: Peptide stacking should only be done under the guidance of a qualified healthcare professional. Individual responses may vary.